Randomized Contolled Study Shows Neostigmine Is An Effective Treatment For Acute Colonic Pseudo-Obstruction

May 25, 1999

Researchers at the University of Washington School of Medicine have performed the first randomized controlled clinical trial showing that a painful and even life-threatening bowel condition called acute colonic pseudo-obstruction can be effectively treated with intravenous neostigmine.

Results of the study will be published in the July 15 issue of the New England Journal of Medicine. However, the journal is releasing the study seven weeks early on its Web site, http://www.nejm.org, to ensure that doctors who treat the condition are notified as quickly as possible. The article is entitled "Neostigmine for the Treatment of Acute Colonic Pseudo-Obstruction."

Acute colonic pseudo-obstruction occurs in some hospitalized patients following surgery or severe medical illness. The condition is caused by a loss of normal motility or spontaneous bowel action. Also called Ogilvie's syndrome, it causes a severely distended colon (large intestine).

If conservative treatments to restore normal bowel function are not successful, some patients require colonic decompression by emergency colonoscopy or surgery, to prevent ischemia (cutoff of blood supply to the bowel) or perforation of the bowel. Some 3 percent of patients with the condition suffer a perforated bowel and half of those patients die.

In this prospective, double-blind, placebo-controlled trial, Drs. Robert J. Ponec, Michael D. Sanders and Michael B. Kimmey of the Division of Gastroenterology at University of Washington Medical Center confirm earlier uncontrolled studies showing that treatment with intravenous neostigmine is effective in relieving the condition.

The UW study involved 21 patients with a wide range of medical and surgical diagnoses, who had marked abdominal distention and dilated colon and who had failed to improve after 24 hours of conservative treatment. (Conservative treatment included nothing by mouth, nasogastric suction, intravenous fluids, electrolyte replacement and, where possible, withdrawal of drugs that adversely affect the colon's motility, such as narcotic pain relievers.)

They were randomly assigned to treatment with either intravenous neostigmine or saline solution as a placebo (inactive substance). A physician who was unaware of which treatment the patient had received recorded clinical response, abdominal circumference, and X-ray measurements of the colon. Patients who did not respond to the initial injection were eligible to receive neostigmine three hours later.

The study showed that colonic decompression was achieved in 10 of 11 patients who received neostigmine, compared to none of the 10 patients who received placebo, as determined by clinical response, and reductions in abdominal girth and colonic diameters.

The median time to clinical response, in the form of passing stool or gas, was four minutes. Seven of the patients who had received placebo later received neostigmine, with successful results. One patient who originally received the drug required a second open-label dose, with successful results. The most frequent side effects of the drug were mild abdominal pain and excessive salivation. Slowing of the heart beat in two patients required treatment with atropine.

"Our study confirms earlier studies showing that neostigmine is an effective, safe and inexpensive way to decompress the colon in patients with acute colonic pseudo-obstruction," said Kimmey, who is professor of medicine/gastroenterology at UW School of Medicine and director of GI endoscopy at UW Medical Center. "It should be considered prior to colonoscopy in patients with acute colonic pseudo-obstruction who have not responded to conservative management."
-end-


University of Washington

Related Placebo Articles from Brightsurf:

Effect of fluvoxamine vs placebo on clinical deterioration in outpatients with symptomatic COVID-19
This randomized trial compares the effects of fluvoxamine, a selective serotonin reuptake inhibitor with immunomodulatory effects, versus placebo on a composite of dyspnea or pneumonia and oxygen desaturation among adult outpatients with polymerase chain reaction-confirmed mild COVID-19 illness.

Hydroxychloroquine no more effective than placebo in preventing COVID-19
Clinical trial with COVID-19 testing of participants shows health care workers in contact with coronavirus patients who took hydroxychloroquine each day did not reduce their rate of infection.

Compared to placebo, vitamin D has no benefit for severe asthma attacks
Contrary to earlier observational results, vitamin D supplements do not prevent severe asthma attacks in at-risk children, according to the first placebo-controlled clinical trial to test this relationship.

UMN trial shows hydroxychloroquine has no benefit over placebo in preventing COVID-19
Today, University of Minnesota Medical School researchers published the results from the first randomized clinical trial testing hydroxychloroquine for the post-exposure prevention of COVID-19.

The placebo effect and psychedelic drugs: tripping on nothing?
A new study from McGill suggests that, in the right context, some people may experience psychedelic-like effects from placebos alone.

Methotrexate reduces joint damage progression over placebo in erosive hand OA
According to new research findings presented at the 2019 ACR/ARP Annual Meeting, methotrexate did not demonstrate superior efficacy over placebo for pain relief and function evolution at three and 12 months in patients with erosive hand osteoarthritis, but did significantly reduce the progression of joint damage over placebo and seems to facilitate bone remodeling in these patients.

Botulinum toxin reduces chronic migraine attacks, compared to placebo
A growing body of evidence supports the effectiveness of botulinum toxin injections in reducing the frequency of chronic migraine headaches, concludes an updated review and analysis in the January issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).

Opioids vs. placebo, nonopioid alternatives for chronic noncancer pain
An estimated 50 million adults in the United States were living with chronic noncancer pain in 2016 and many of them were prescribed opioid medications, even though a clinical benefit is uncertain.

Probiotic no better than placebo for acute gastroenteritis in children
While probiotics are often used to treat acute gastroenteritis (also known as infectious diarrhea) in children, the latest evidence shows no significant differences in outcomes, compared to a placebo.

Most common shoulder operation is no more beneficial than placebo surgery
In a landmark study published this week in the BMJ, Finnish researchers show that one of the most common surgical procedures in the Western world is probably unnecessary.

Read More: Placebo News and Placebo Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.